Immunocore Holdings plc — Company profile
Healthcare · Biotechnology · United Kingdom
Last price 30.49 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.57B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Details
| Name | Immunocore Holdings plc |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 524 |
| Founded | 2008 |
| Ipo Date | 2021-02-05 |
| Ceo | Bahija Jallal |
| Country | United Kingdom |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 26.00 |
| Isin | US45258D1054 |
| Cusip | 45258D105 |
| Cik | 1671927 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Dr. Bahija Jallal Ph.D. | Chief Executive Officer and Executive Director |
| Travis Alan Coy M.B.A. | Chief Financial Officer, Executive Vice President and Head of Corporate Development |
| Dr. Kripa Ram Ph.D. | Executive Vice President and Chief Operating Officer |
| John Goll III | SVice President, Finance and Chief Accounting Officer |
| Annelise Vuidepot Ph.D. | Chief Science and Technology Officer and Milton Park Site Head |
| Sean D. Buckley | Vice President and Chief Information Officer |
| Ryan Baker | Vice President of Investor Relations |
| Lily Margaret Hepworth | Executive Vice President, General Counsel and Company Secretary |
| Elizabeth Varki Jobes Esq., J.D. | Chief Compliance Officer |
| Sébastien Desprez | Vice President of Communications |
Contact
| Address | 92 Park Drive, Milton Park, Abingdon, OX14 4RY, United Kingdom |
| Phone | 44 12 3543 8600 |
| Website | https://www.immunocore.com |